Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.

Alexander JH, Ferguson TB Jr, Joseph DM, Mack MJ, Wolf RK, Gibson CM, Gennevois D, Lorenz TJ, Harrington RA, Peterson ED, Lee KL, Califf RM, Kouchoukos NT; PREVENT IV Investigators.

Am Heart J. 2005 Oct;150(4):643-9.

PMID:
16209958
2.

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.

Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators.

JAMA. 2005 Nov 16;294(19):2446-54.

PMID:
16287955
3.

Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV.

Magee MJ, Alexander JH, Hafley G, Ferguson TB Jr, Gibson CM, Harrington RA, Peterson ED, Califf RM, Kouchoukos NT, Herbert MA, Mack MJ; PREVENT IV Investigators.

Ann Thorac Surg. 2008 Feb;85(2):494-9; discussion 499-500. doi: 10.1016/j.athoracsur.2007.10.008.

PMID:
18222251
4.

Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV).

Yau JM, Alexander JH, Hafley G, Mahaffey KW, Mack MJ, Kouchoukos N, Goyal A, Peterson ED, Gibson CM, Califf RM, Harrington RA, Ferguson TB; PREVENT IV Investigators.

Am J Cardiol. 2008 Sep 1;102(5):546-51. doi: 10.1016/j.amjcard.2008.04.069. Epub 2008 Jul 2.

PMID:
18721510
5.

Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery.

Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, Namini H, Hamdan AD, Roddy SP, Belkin M, Berceli SA, DeMasi RJ, Samson RH, Berman SS; PREVENT III Investigators.

J Vasc Surg. 2006 Apr;43(4):742-751; discussion 751.

6.

Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial.

Mehta RH, Ferguson TB, Lopes RD, Hafley GE, Mack MJ, Kouchoukos NT, Gibson CM, Harrington RA, Califf RM, Peterson ED, Alexander JH; Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Investigators.

Circulation. 2011 Jul 19;124(3):280-8. doi: 10.1161/CIRCULATIONAHA.110.991299. Epub 2011 Jun 27.

7.

A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale.

Mehta RH, Alexander JH, Emery R, Ellis SJ, Hasselblad V, Khalil A, Carrier M, Harrington RA, Tardif JC; MEND-CABG II Investigators.

Am Heart J. 2008 Apr;155(4):600-8. doi: 10.1016/j.ahj.2008.01.002. Epub 2008 Feb 21.

PMID:
18371465
8.

Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.

Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, Lorenz TJ, Alexander JH.

Am Heart J. 2012 Sep;164(3):379-386.e1. doi: 10.1016/j.ahj.2012.05.019.

9.

Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters.

Olenchock SA Jr, Karmpaliotis D, Gibson WJ, Murphy SA, Southard MC, Ciaglo L, Buros J, Mack MJ, Alexander JH, Harrington RA, Califf RM, Kouchoukos NT, Ferguson TB Jr, Gibson CM.

Ann Thorac Surg. 2008 Feb;85(2):520-4. doi: 10.1016/j.athoracsur.2007.10.061.

PMID:
18222256
11.

Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery.

Mehta RH, Hafley GE, Gibson CM, Harrington RA, Peterson ED, Mack MJ, Kouchoukos NT, Califf RM, Ferguson TB Jr, Alexander JH; Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT)-IV Investigators.

J Thorac Cardiovasc Surg. 2008 Nov;136(5):1149-55. doi: 10.1016/j.jtcvs.2008.02.085. Epub 2008 Aug 27.

12.

Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure.

Conte MS, Lorenz TJ, Bandyk DF, Clowes AW, Moneta GL, Seely BL.

Vasc Endovascular Surg. 2005 Jan-Feb;39(1):15-23.

13.

Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial.

Harskamp RE, Alexander JH, Schulte PJ, Brophy CM, Mack MJ, Peterson ED, Williams JB, Gibson CM, Califf RM, Kouchoukos NT, Harrington RA, Ferguson TB Jr, Lopes RD.

JAMA Surg. 2014 Aug;149(8):798-805. doi: 10.1001/jamasurg.2014.87. Erratum in: JAMA Surg. 2014 Sep;149(9):961.

14.

The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase.

Ong AT, Serruys PW, Mohr FW, Morice MC, Kappetein AP, Holmes DR Jr, Mack MJ, van den Brand M, Morel MA, van Es GA, Kleijne J, Koglin J, Russell ME.

Am Heart J. 2006 Jun;151(6):1194-204.

PMID:
16781219
15.

A study design to assess the safety and efficacy of on-pump versus off-pump coronary bypass grafting: the ROOBY trial.

Novitzky D, Shroyer AL, Collins JF, McDonald GO, Lucke J, Hattler B, Kozora E, Bradham DD, Baltz J, Grover FL; VA #517 Randomized On/Off Bypass (ROOBY) Study Group.

Clin Trials. 2007;4(1):81-91.

PMID:
17327248
16.
17.

Increased risk associated with combined carotid endarterectomy and coronary artery bypass graft surgery: a propensity-matched comparison with isolated coronary artery bypass graft surgery.

Cywinski JB, Koch CG, Krajewski LP, Smedira N, Li L, Starr NJ.

J Cardiothorac Vasc Anesth. 2006 Dec;20(6):796-802. Epub 2006 May 4.

PMID:
17138083
18.

Revascularization in severe left ventricular dysfunction: outcome comparison of drug-eluting stent implantation versus coronary artery by-pass grafting.

Gioia G, Matthai W, Gillin K, Dralle J, Benassi A, Gioia MF, White J.

Catheter Cardiovasc Interv. 2007 Jul 1;70(1):26-33.

PMID:
17585381
19.

Deterioration of regional wall motion immediately after coronary artery bypass graft surgery is associated with long-term major adverse cardiac events.

Swaminathan M, Morris RW, De Meyts DD, Podgoreanu MV, Jollis JG, Grocott HP, Milano CA, Newman MF, Mathew JP.

Anesthesiology. 2007 Nov;107(5):739-45.

PMID:
18073549
20.

Prophylactic intravenous magnesium sulphate in addition to oral {beta}-blockade does not prevent atrial arrhythmias after coronary artery or valvular heart surgery: a randomized, controlled trial.

Cook RC, Humphries KH, Gin K, Janusz MT, Slavik RS, Bernstein V, Tholin M, Lee MK.

Circulation. 2009 Sep 15;120(11 Suppl):S163-9. doi: 10.1161/CIRCULATIONAHA.108.841221.

Items per page

Supplemental Content

Write to the Help Desk